Background: Hyponatremia is frequent in acute stroke patients, and it is associated with worse outcomes and increased mortality. Summary: Nonstroke-related causes of hyponatremia include patients’ comorbidities and concomitant medications, such as diabetes mellitus, chronic kidney disease, heart failure, and thiazides. During hospitalization, “inappropriate” administration of hypotonic solutions, poor solute intake, infections, and other drugs, such as mannitol, could also lower sodium levels in patients with acute stroke. On the other hand, secondary adrenal insufficiency due to pituitary ischemia or hemorrhage, syndrome of inappropriate antidiuretic hormone secretion, and cerebral salt wasting are additional stroke-related causes of hyponatremia. Although it is yet unclear whether the appropriate restoration of sodium level improves outcomes in patients with acute stroke, the restoration of the volume depletion remains the cornerstone of treatment in hypovolemic hyponatremia. In case of hyper- and euvolemic hyponatremia, apart from the correction of the underlying cause (e.g., withdrawal of an offending drug), fluid restriction, administration of hypertonic solution, loop diuretics, and vasopressin-receptor antagonists (vaptans) are among the therapeutic options. Key Messages: Hyponatremia is frequent in patients with acute stroke. The plethora of underlying etiologies warrants a careful differential diagnosis which should take into consideration comorbidities, concurrent medication, findings from the clinical examination, and laboratory measurements, which in turn will guide management decisions. However, it is yet unclear whether the appropriate restoration of sodium level improves outcomes in patients with acute stroke.

Keywords:
Hyponatremia, Ischemic, Hemorrhagic, Stroke, Mortality
1.
Liamis G, Rodenburg EM, Hofman A, Zietse R, Stricker BH, Hoorn EJ. Electrolyte disorders in community subjects: prevalence and risk factors.
Am J Med
. 2013 Mar;126(3):256–63.
2.
Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia.
Am J Med
. 2006 Jul;119(7 Suppl 1):S30–5.
3.
Liamis G, Milionis HJ, Elisaf M. Hyponatremia in patients with infectious diseases.
J Infect
. 2011 Nov;63(5):327–35.
4.
Fofi L, Dall’armi V, Durastanti L, Valenza A, Lorenzano S, Prencipe M, et al. An observational study on electrolyte disorders in the acute phase of ischemic stroke and their prognostic value.
J Clin Neurosci
. 2012 Apr;19(4):513–6.
5.
Huang WY, Weng WC, Peng TI, Chien YY, Wu CL, Lee M, et al. Association of hyponatremia in acute stroke stage with three-year mortality in patients with first-ever ischemic stroke.
Cerebrovasc Dis
. 2012;34(1):55–62.
6.
Rodrigues B, Staff I, Fortunato G, McCullough LD. Hyponatremia in the prognosis of acute ischemic stroke.
J Stroke Cerebrovasc Dis
. 2014 May-Jun;23(5):850–4.
7.
Lasek-Bal A, Holecki M, Kret B, Hawrot-Kawecka A, Duława J. Evaluation of influence of chronic kidney disease and sodium disturbances on clinical course of acute and sub-acute stage first-ever ischemic stroke.
Med Sci Monit
. 2014 Aug;20:1389–94.
8.
Bei HZ, You SJ, Zheng D, Zhong CK, Du HP, Zhang Y, et al. Prognostic role of hypochloremia in acute ischemic stroke patients.
Acta Neurol Scand
. 2017 Dec;136(6):672–9.
9.
Gao H, Sun X, Li W, Gao Q, Zhang J, Zhang Y, et al. Development and validation of a risk score to predict 30-day mortality in patients with atrial fibrillation-related stroke: GPS-GF score.
Neurol Res
. 2018 Jul;40(7):532–40.
10.
Soiza RL, Cumming K, Clark AB, Bettencourt-Silva JH, Metcalf AK, Bowles KM, et al.: Hyponatremia predicts mortality after stroke. Int J Stroke. 2015 Oct;10 Suppl A100:50–5.
11.
Kuramatsu JB, Bobinger T, Volbers B, Staykov D, Lücking H, Kloska SP, et al. Hyponatremia is an independent predictor of in-hospital mortality in spontaneous intracerebral hemorrhage.
Stroke
. 2014 May;45(5):1285–91.
12.
Gray JR, Morbitzer KA, Liu-DeRyke X, Parker D Jr, Zimmerman LH, Rhoney DH. Hyponatremia in Patients with Spontaneous Intracerebral Hemorrhage.
J Clin Med
. 2014 Nov;3(4):1322–32.
13.
Carcel C, Sato S, Zheng D, Heeley E, Arima H, Yang J, et al.; Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial 2 Investigators. Prognostic Significance of Hyponatremia in Acute Intracerebral Hemorrhage: Pooled Analysis of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial Studies.
Crit Care Med
. 2016 Jul;44(7):1388–94.
14.
Alam MN, Uddin MJ, Rahman KM, Ahmed S, Akhter M, Nahar N, et al. Electrolyte changes in stroke.
Mymensingh Med J
. 2012 Oct;21(4):594–9.
15.
Kalita J, Singh RK, Misra UK. Cerebral Salt Wasting Is the Most Common Cause of Hyponatremia in Stroke.
J Stroke Cerebrovasc Dis
. 2017 May;26(5):1026–32.
16.
Saleem S, Yousuf I, Gul A, Gupta S, Verma S. Hyponatremia in stroke.
Ann Indian Acad Neurol
. 2014 Jan;17(1):55–7.
17.
Shah A, Sabir S, Artani M, Salam O, Khan S, Rizwan A. Significance of Hyponatremia as an Independent Factor in Predicting Short-term Mortality in Patients with Hemorrhagic Stroke.
Cureus
. 2019 Apr;11(4):e4549.
18.
Kesarwani M, Perez A, Lopez VA, Wong ND, Franklin SS. Cardiovascular comorbidities and blood pressure control in stroke survivors.
J Hypertens
. 2009 May;27(5):1056–63.
19.
Liamis G, Milionis H, Elisaf M. Blood pressure drug therapy and electrolyte disturbances.
Int J Clin Pract
. 2008 Oct;62(10):1572–80.
20.
Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia.
Am J Kidney Dis
. 2008 Jul;52(1):144–53.
21.
Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypernatraemia.
NDT Plus
. 2009 Oct;2(5):339–46.
22.
Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al.; Hyponatraemia Guideline Development Group. Clinical practice guideline on diagnosis and treatment of hyponatraemia.
Eur J Endocrinol
. 2014 Feb;170(3):G1–47.
23.
Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations.
Am J Med
. 2013 Oct;126(10 Suppl 1):S1–42.
24.
Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al.; American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.
Stroke
. 2018 Mar;49(3):e46–110.
25.
Tsai SF, Shu KH. Mannitol-induced acute renal failure.
Clin Nephrol
. 2010 Jul;74(1):70–3.
26.
Shi J, Qian J, Li H, Luo H, Luo W, Lin Z. Renal tubular epithelial cells injury induced by mannitol and its potential mechanism.
Ren Fail
. 2018 Nov;40(1):85–91.
27.
Liamis G, Tsimihodimos V, Doumas M, Spyrou A, Bairaktari E, Elisaf M. Clinical and laboratory characteristics of hypernatraemia in an internal medicine clinic.
Nephrol Dial Transplant
. 2008 Jan;23(1):136–43.
28.
Hannon MJ, Behan LA, O’Brien MM, Tormey W, Ball SG, Javadpour M, et al. Hyponatremia following mild/moderate subarachnoid hemorrhage is due to SIAD and glucocorticoid deficiency and not cerebral salt wasting.
J Clin Endocrinol Metab
. 2014 Jan;99(1):291–8.
29.
Verbalis JG. Hyponatremia with intracranial disease: not often cerebral salt wasting.
J Clin Endocrinol Metab
. 2014 Jan;99(1):59–62.
30.
Maesaka JK, Imbriano LJ, Miyawaki N. Determining Fractional Urate Excretion Rates in Hyponatremic Conditions and Improved Methods to Distinguish Cerebral/Renal Salt Wasting From the Syndrome of Inappropriate Secretion of Antidiuretic Hormone.
Front Med (Lausanne)
. 2018 Nov;5:319.
31.
Maesaka JK, Imbriano L, Mattana J, Gallagher D, Bade N, Sharif S. Differentiating SIADH from Cerebral/Renal Salt Wasting: Failure of the Volume Approach and Need for a New Approach to Hyponatremia.
J Clin Med
. 2014 Dec;3(4):1373–85.
32.
Xu Q, Tian Y, Peng H, Li H. Copeptin as a biomarker for prediction of prognosis of acute ischemic stroke and transient ischemic attack: a meta-analysis.
Hypertens Res
. 2017 May;40(5):465–71.
33.
Fenske W, Störk S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatremia.
J Clin Endocrinol Metab
. 2009 Jan;94(1):123–9.
34.
Nigro N, Winzeler B, Suter-Widmer I, Schuetz P, Arici B, Bally M, et al. Evaluation of copeptin and commonly used laboratory parameters for the differential diagnosis of profound hyponatraemia in hospitalized patients: ‘The Co-MED Study’.
Clin Endocrinol (Oxf)
. 2017 Mar;86(3):456–62.
35.
Mazza A, Pessina AC, Pavei A, Scarpa R, Tikhonoff V, Casiglia E. Predictors of stroke mortality in elderly people from the general population. The CArdiovascular STudy in the ELderly.
Eur J Epidemiol
. 2001;17(12):1097–104.
36.
Sajadieh A, Binici Z, Mouridsen MR, Nielsen OW, Hansen JF, Haugaard SB. Mild hyponatremia carries a poor prognosis in community subjects.
Am J Med
. 2009 Jul;122(7):679–86.
37.
Wannamethee G, Whincup PH, Shaper AG, Lever AF. Serum sodium concentration and risk of stroke in middle-aged males.
J Hypertens
. 1994 Aug;12(8):971–9.
38.
Hoorn EJ, Zietse R. Hyponatremia and mortality: how innocent is the bystander?
Clin J Am Soc Nephrol
. 2011 May;6(5):951–3.
39.
Chen Z, Jia Q, Liu C. Association of Hyponatremia and Risk of Short- and Long-Term Mortality in Patients with Stroke: A Systematic Review and Meta-Analysis.
J Stroke Cerebrovasc Dis
. 2019 Jun;28(6):1674–83.
40.
Greenberg A, Verbalis JG, Amin AN, Burst VR, Chiodo JA 3rd, Chiong JR, et al. Current treatment practice and outcomes. Report of the hyponatremia registry.
Kidney Int
. 2015 Jul;88(1):167–77.
41.
Filippatos TD, Liamis G, Christopoulou F, Elisaf MS. Ten common pitfalls in the evaluation of patients with hyponatremia.
Eur J Intern Med
. 2016 Apr;29:22–5.
42.
Liamis G, Liberopoulos E, Barkas F, Elisaf M. Spurious electrolyte disorders: a diagnostic challenge for clinicians.
Am J Nephrol
. 2013;38(1):50–7.
43.
Filippatos T, Elisaf M, Liamis G. Pharmacological management of hyponatremia.
Expert Opin Pharmacother
. 2018 Aug;19(12):1337–44.
44.
Sterns RH, Silver SM. Cerebral salt wasting versus SIADH: what difference?
J Am Soc Nephrol
. 2008 Feb;19(2):194–6.
45.
Musch W, Decaux G. Treating the syndrome of inappropriate ADH secretion with isotonic saline. QJM 1998;91:749–53.
46.
Decaux G, Andres C, Gankam Kengne F, Soupart A. Treatment of euvolemic hyponatremia in the intensive care unit by urea.
Crit Care
. 2010;14(5):R184.
47.
Pierrakos C, Taccone FS, Decaux G, Vincent JL, Brimioulle S. Urea for treatment of acute SIADH in patients with subarachnoid hemorrhage: a single-center experience.
Ann Intensive Care
. 2012 May;2(1):13.
48.
Annoni F, Fontana V, Brimioulle S, Creteur J, Vincent JL, Taccone FS. Early Effects of Enteral Urea on Intracranial Pressure in Patients With Acute Brain Injury and Hyponatremia.
J Neurosurg Anesthesiol
. 2017 Oct;29(4):400–5.
49.
Gankam Kengne F, Couturier BS, Soupart A, Decaux G. Urea minimizes brain complications following rapid correction of chronic hyponatremia compared with vasopressin antagonist or hypertonic saline.
Kidney Int
. 2015 Feb;87(2):323–31.
50.
Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, et al.; SALT Investigators. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
N Engl J Med
. 2006 Nov;355(20):2099–112.
51.
Zeynalov E, Jones SM, Seo JW, Snell LD, Elliott JP. Arginine-Vasopressin Receptor Blocker Conivaptan Reduces Brain Edema and Blood-Brain Barrier Disruption after Experimental Stroke in Mice.
PLoS One
. 2015 Aug;10(8):e0136121.
52.
Decker D, Collier L, Lau T, Olivera R, Roma G, Leonardo C, et al. The Effects of Clinically Relevant Hypertonic Saline and Conivaptan Administration on Ischemic Stroke.
Acta Neurochir Suppl (Wien)
. 2016;121:243–50.
53.
Li-Ng M, Verbalis JG. Conivaptan: evidence supporting its therapeutic use in hyponatremia.
Core Evid
. 2010 Jun;4:83–92.
54.
Der-Nigoghossian C, Lesch C, Berger K. Effectiveness and Tolerability of Conivaptan and Tolvaptan for the Treatment of Hyponatremia in Neurocritically Ill Patients.
Pharmacotherapy
. 2017 May;37(5):528–34.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.